Europe

In Europe, and around the world, there is a growing expectation in society that companies, organisations and individuals act in a transparent manner. This applies to relationships between the pharmaceutical industry, healthcare professionals (HCPs) and healthcare organisations (HCOs) where all interactions should be conducted with integrity and transparency.

Please select...

GSK fully supports the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations. We believe that it will help create a better understanding about how the pharmaceutical industry partners and collaborates with HCPs and HCOs, and so increase confidence in the way that industry and the healthcare profession works together.

Dr waheel, employee
Dr Waheed Jamal, VP European Medical

The importance of industry collaboration with HCPs

Cooperation between pharmaceutical companies, regulators, HCPs, HCOs and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been and will always remain valuable partners for GSK. As experts in their field, they provide us with first hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet disparate patient and public health needs.

Supporting greater transparency in Europe

Over the past few years we have begun to disclose information, on an individual or aggregate basis, regarding transfers of value made to HCPs and HCOs in a number of countries. This involves 30 European countries plus Russia and Ukraine. Internationally, it includes Australia, Japan and the USA with Canada disclosing payments for the first time this year. The EFPIA disclosure initiative builds on these national initiatives, as part of an evolution towards greater transparency.

Under the EFPIA Disclosure Code, from 2016 EFPIA member companies have pledged to disclose the transfers of value they make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This will include, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development will be disclosed on as an aggregate number.

The first disclosures – of payments made during 2015 – were made by 30 June 2016. The information was published on a public platform; either the company’s own website or, as was the case in some countries, a central platform combining data from different companies. We are following the same process for disclosures of 2016 data of which all disclosures must be made by 30 June 2017.

Our approach to EFPIA disclosure

As part of our goal to be one of the most innovative, best performing and trusted healthcare companies in the world, we seek to meet society’s evolving expectations, bring greater transparency to an already well-regulated industry, and strengthen our relationships with HCPs and HCOs for future collaboration.

We also recognise the need to further increase transparency and public confidence in our business. That is why we continue to reform our commercial operating model, which in Europe includes more clarity around the nature of our relationships with HCPs and HCOs.

It is with this mindset that we implement the EFPIA Disclosure Code. We apply a “no disclosure consent, no contract” principle to enable and drive disclosure at the individual level. In practice this means:

  • Where individual named disclosure is required under the EFPIA Disclosure Code, we will actively seek the necessary consent from each HCP with whom we work.
  • We will not work with HCPs where consent is not given. Where consent is given but subsequently withdrawn we will not then work with that HCP on activities covered by individual disclosure for a period of one year.

Going beyond transparency

We have committed to going beyond the requirements set out in the EFPIA disclosure code by continuing to make additional, industry leading changes to our business model, including:

  • a new incentive model for our sales professionals, based on their scientific knowledge and quality of support to HCPs;
  • stopping payments to HCPs to speak about our prescription medicines and disease areas to audiences who prescribe or influence prescribing as of 1 January 2016; and
  • stopping provision of financial support directly to individual HCPs to attend medical congresses.

Instead, we have ensured our own medics have had and will continue to have more time to share their expertise and answer questions from other HCPs. We are also developing new digital and real-time applications to improve delivery of medical information to HCPs, and are providing arms length funding to independent bodies which select HCPs to attend medical congresses for medical education purposes.

We will continue to work with and pay HCPs for non-promotional activities. This includes conducting clinical research and seeking advice on the clinical relevance and appropriate communication of the results of our research, as well as identifying new research areas.

These interactions are an essential part of how we ensure medicines we develop meet patients’ needs.

What will this mean for patients?

We believe our continued commitment to greater transparency and our new approach to working with HCPs will provide greater confidence that industry is acting in the best interests of patients and an improved understanding about the importance of collaboration between pharmaceutical companies and the medical profession.

EFPIA Disclosure Code 2017 Self-Certification Scheme

We have published disclosure reports in line with the EFPIA Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations.

Click on the appropriate section in the table below to view GSK’s disclosure reports in line with the EFPIA Disclosure Code. Reports may appear in the country’s local language. For translations or other enquiries, contact names have been provided.

Please note there may be slight differences between disclosures figures reported on this page versus other sources (such as the UK’s ABPI disclosure platform for example). Please see the methodological notes for further explanation of what we are disclosing. Please view the infographic displaying an overview of GSK’s approach to transparency and break down of the combined total of spend / ToV to;

  • Unique HCP’s (named individual and aggregate)
  • Unique HCO’s (named individual and aggregate)
  • Research aggregate, if applicable

Find out how disclosing information on payments made to doctors has already had positive effects in Europe.

Back to top